Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting

B BOSTON, April 28, 2026 /PRNewswire/ — Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced it will present two…
posteditor
posteditor
Articles: 17424

Other News